Our Blog

Mesoblast see strong commercialisation revenues for the quarter

30 Jul 2019 – Mesoblast (ASX:MSB) today reported its operational highlights for their fourth quarter showing growth in revenues achieved by their Japanese partner in the treatment of acute graft versus host disease in the first three years post launch.


Source: Finance News Network

Share this post